BioSpace News Archive

Invitation to Essity’s Q3 2018 Press Conference

The press conference held in connection with the publication of Essity’s interim report for the third quarter of 2018 will also be available via webcast and it is possible to join by phone.

October 1, 2018
·
1 min read
Infiniti Research Highlights the Impact of Technology on Healthcare in Their Latest Article

Infiniti Research, a world-renowned market intelligence solutions provider, has announced the completion of their latest article on the impact of technology on healthcare.

October 1, 2018
·
3 min read
Business

Thermo Fisher Scientific Showcases Innovations in Proteomic Research at HUPO 2018

Thermo Fisher Scientific is showcasing its latest solutions and technologies at the 17th Human Proteome Organization (HUPO) World Congress (booth #401), September 30-October 3 at the Loews Royal Pacific, Orlando, Florida.

October 1, 2018
·
5 min read
Genetown

Homology Medicines to Present at Upcoming October 2018 Conferences

Homology Medicines, Inc. announced today that Homology will present at the following conferences

October 1, 2018
·
1 min read
Policy

Dr. Reddy’s Laboratories Announces That It Has Regained Worldwide Rights to DFA-02

Dr. Reddy’s Laboratories Ltd. today announced the termination of the license granted to Armis Biopharma, Inc.

October 1, 2018
·
2 min read
Forbion Closes Oversubscribed Fourth Life Sciences VC Fund at EUR 360 million

Investment focus is on new drugs and technologies that will truly impact the future of medicine

October 1, 2018
·
3 min read
Deals

RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering

RXi Pharmaceuticals Corporation today announced the pricing of an underwritten public offering of 21,428,572 units at a price to the public of $0.70 per unit.

October 1, 2018
·
5 min read
Business

Pfizer Announces CEO Succession

Effective January 1, 2019, Dr. Albert Bourla to become Chief Executive Officer (CEO) and Ian Read to serve as Executive Chairman of the Board of Directors

October 1, 2018
·
7 min read
Drug Development

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

ADCETRIS in Combination with Chemotherapy Achieved Primary Endpoint, Demonstrating a Statistically Significant Improvement in Progression-Free Survival Compared to a Standard of Care Chemotherapy

October 1, 2018
·
25 min read
Pharm Country

Lannett Launches Five New Products In Fiscal 2019 First Quarter

Lannett Company, Inc. today announced that it commenced marketing five new products in its recently completed fiscal 2019 first quarter, bringing to 12 the total number of products launched since January 1, 2018.

October 1, 2018
·
2 min read